Emerging evidence suggests that the extrapulmonary effects of pulmonary arterial hypertension may manifest in the form of vascular dysfunction in systemic circulation, metabolic/endocrine dysfunction, and skeletal and respiratory muscle dysfunction.
The optimal treatment approach for pulmonary arterial hypertension in pediatric patients depends upon the severity and underlying etiology of the disease.
The most recent CHEST guidelines on pulmonary arterial hypertension treatment support the integration of palliative care, noting significant improvements in outcomes observed in other pulmonary diseases, including lung cancer.
Positive topline data from the phase 2b study of INOpulse® delivery system announced for the treatment of pulmonary hypertension associated with pulmonary fibrosis.
Incorporating preoperative right heart measurements into the standard pulmonary hypertension risk estimation model may allow for better risk stratification following aortic valve replacement.
Systemic anticoagulation was found to improve quality-adjusted life years among patients with idiopathic pulmonary arterial hypertension but not among those with connective tissue disease-associated pulmonary arterial hypertension.
Pulmonary arterial hypertension with systemic sclerosis associated-survival improved over time among patients aged 70 years or younger, but not among the elderly.
